The New Zealand Institute for Plant and Food Research Limited

Southern Horticultural Research Institute

Pacific Edge Limited

Satish Kumar

Tran Thi Oanh Yen

Thi Nguyen Ngoc

Nguyen Nhat Truong

Huynh Van Chanh

Laimonis Kavalieris

Mark Dalphin

Paul O'Sullivan

David Darling

James Miller Suttie

A new and distinct dragon fruit plant is described. The variety resulted from selection among a population of seedlings derived from a controlled cross carried out in 2013 between RF (seed parent) (not patented) and 'LD5' (pollen parent) (not patented) located in Tien Giang, Viet Nam. The variety was selected due to its appearance, eating quality and canker tolerance.

Dragon fruit plant named 'DF2'

A new and distinct dragon fruit plant is described. The variety resulted from selection among a population of seedlings derived from a controlled cross carried out in 2013 between RF (seed parent) (not patented) and 'LD1' (pollen parent) (not patented) in Tien Giang, Viet Nam. The variety was selected due to its appearance, eating quality and canker tolerance.

Dragon fruit plant named 'DF 16'

A new and distinct dragon fruit plant is described. The variety resulted from selection among a population of seedlings derived from a controlled cross carried out in 2013 between RF (seed parent) (not patented) and 'LD5' (pollen parent) (not patented) located in Tien Qiang, Viet Nam. The variety was selected due to its external appearance, pink strip under the skin, eating quality and canker tolerance.

Dragon fruit plant named 'DF14'

New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the 'G+P INDEX.' The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.

Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof

Growing community of inventors

Havelock North, New Zealand

Satish Kumar